As the most challenging disease to spell and pronounce continues its global expansion, access to the only approved chikungunya virus vaccine is becoming broader.
The Coalition for Epidemic Preparedness Innovations (CEPI) has expanded its support to provide expanded access to the world’s first chikungunya vaccine, IXCHIQ®.
IXCHIQ (VLA1553) is a monovalent, single-dose, live-attenuated chikungunya vaccine that the U.S. Food and Drug Administration approved in November 2023.
Read More
